Please assess the completion status of the following clinical trial:

Trial Title: A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with GHD as defined in the consensus guidelines for the diagnosis and treatment of adults with GHD~* Stable human growth hormone (hGH) replacement therapy for at least 3 months~Exclusion Criteria:~* Participation in another clinical trial within 3 months or receipt of any investigational medicinal product within 3 months prior to randomisation~* Active malignant disease or malignant disease within the last 5 years with exception of fully treated local basal cell carcinoma or carcinoma in situ of cervix~* Proliferative retinopathy judged by retina-photo within the last year - only with concomitant diabetes~* Heart insufficiency, New York Heart Association (NYHA) class above 2~* Adults with GHD with poorly controlled diabetes mellitus with a glycosylated haemoglobin (HbA1c) 64 mmol/mol (8.0%) and/or insulin treatment~* Stable pituitary replacement therapy for less than 3 months

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- NNC0195-0092 (somapacitan) (Type: EXPERIMENTAL): None
- Norditropin NordiFlex® (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).